Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Thomas Fuller | Lightrocket | Getty Images Replimune plans to resubmit its melanoma drug to the Food and Drug Administration for review after a leadership exodus at the agency, the company said Friday. The FDA twice rejected Replimune’s melanoma treatment under the previous FDA leadership, […]
Health
